An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma

• Published in: Acta pharmaceutica Sinica. B 2023-12, Vol.13 (12), p.5091-5106
• Main Authors: Qiu, Qiujun, Chen, Sunhui, He, Huining, Chen, Jixiang, Ding, Xinyi, Wang, Dongdong, Yang, Jiangang, Guo, Pengcheng, Li, Yang, Kim, Jisu, Sheng, Jianyong, Gao, Chao, Yin, Bo, Zheng, Shihao, Wang, Jianxin
• Format: Article
• Language: English
• Subjects: Antigen-capturing nanoparticles; Biomaterial; Glioblastoma; Immune signal-amplifying system; Immunotherapy; Original; Postoperative relapse; Recombinant chemokines; Vaccine
• ISSN: 2211-3835; 2211-3843
• DOI: 10.1016/j.apsb.2023.06.010

Despite exciting achievements with some malignancies, immunotherapy for hypoimmunogenic cancers, especially glioblastoma (GBM), remains a formidable clinical challenge. Poor immunogenicity and deficient immune infiltrates are two major limitations to an effective cancer-specific immune response. Herein, we propose that an injectable signal-amplifying nanocomposite/hydrogel system consisting of granulocyte-macrophage colony-stimulating factor and imiquimod-loaded antigen-capturing nanoparticles can simultaneously amplify the chemotactic signal of antigen-presenting cells and the “danger” signal of GBM. We demonstrated the feasibility of this strategy in two scenarios of GBM. In the first scenario, we showed that this simultaneous amplification system, in conjunction with local chemotherapy, enhanced both the immunogenicity and immune infiltrates in a recurrent GBM model; thus, ultimately making a cold GBM hot and suppressing postoperative relapse. Encouraged by excellent efficacy, we further exploited this signal-amplifying system to improve the efficiency of vaccine lysate in the treatment of refractory multiple GBM, a disease with limited clinical treatment options. In general, this biomaterial-based immune signal amplification system represents a unique approach to restore GBM-specific immunity and may provide a beneficial preliminary treatment for other clinically refractory malignancies. An injectable signal-amplifying nanocomposite/hydrogel system consisting of granulocyte-macrophage colony-stimulating factor and imiquimod-loaded antigen-capturing nanoparticles simultaneously amplifies the chemotactic signal of antigen-presenting cells and the “danger” signal of glioblastoma. [Display omitted]